[P1–043]: ELENBECESTAT, A NOVEL ORAL BACE INHIBITOR, HAS NO CLINICALLY MEANINGFUL EFFECT ON QTC INTERVAL UP TO A SUPRATHERAPEUTIC DOSE OF 200 MG. (1st July 2017) - Lai, Robert YK.; Darpo, Borje; Dayal, Satish; Hall, Nancy; Chang, Min‐Kun; Albala, Bruce; Ferry, Jim; Rege, Bhaskar